The Working Group on Bio IT and Big Data will focus on topics that overlap between biotechnology and other industries and draw up policy recommendations on appropriate parameters.
The main aims of this working group are to support the implementation of the German Federal Government’s High Tech Strategy by developing concrete showcase projects in cooperation with the member companies, especially as regards innovation and jobs in small and medium-sized enterprises in the overlapping fields of red and industrial (white) biotechnology; to contribute to the German economic initiative, the Federation of German Industries’ (BDI) Initiative - Innovation Strategies and Knowledge Management; to design a road map for the biotechnology markets; and to work with the CDU Economic Committee’s Commission on Growth and Innovation on the design of a showcase project.
From high-performance sequence analysis to genetic diagnostics and in vitro diagnostics –conditions in the diagnostics sector need to be right so that the German biotech industry can continue to grow.
Equity financing, formulation of new marktet-orientated funding schemes, influencing/creating the fiscal framework, i.a.
Information and experience exchange on practical issues regarding transatlantic themes, contact establishing and event planning together with the American Chamber of Commerce in Germany.
The Working Group on Health Policy deals with business and political parameters, ranging from licensing, paths to reimbursement, market access and care to billing for biopharmaceutical products.
In the Working Group on the Industrial Bioeconomy, white biotechnology firms work with chemical companies, the bioregions and bioclusters on measures to promote the importance of the bioeconomy.
The central aim of the working group Industrial Cell Technology is to promote the name-giving platform technologies of industrial cell technologies.
The topics to be covered by this working group will include the image of biotech entrepreneurs among the public, as well as the contribution made by biotechnological processes to improving nutrition and health and to sustainable industrial manufacturing.
The Working Group on Regulatory Matters aims to promote research on and development of innovative medicinal products by removing unnecessary bureaucracy and current obstacles in the regulatory parameters.
Importance of protection rights for a sustainable and continual innovation in Germany and throughout Europe, reduction of protection right costs for SMEs, removal of current structures in the field of technology transfer that prevent innovation, etc.
The Working Group on Technology Transfer provides representatives of technology transfer organisations, companies, BioRegions and bio clusters with a forum for discussing the transfer of technology between research and biotechnology and between biotechnology and the pharmaceutical sector.